Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Marpai, Inc. filings document material events, capital-structure matters and operating disclosures for a healthcare technology company whose Class A common stock trades on the OTCQX Market under MRAI. Recent Form 8-K reports cover results of operations, material definitive agreements and governance matters.
The filing record includes disclosures on promissory-note financing for working capital, amendments to note terms, officer appointments, and charter changes authorizing blank-check preferred stock. Marpai filings also identify its registered Class A common stock, emerging growth company status in certain reports, and formal risk and compliance references tied to its public-company reporting obligations.
Marpai, Inc. director Eitan Yaron reported an open-market purchase of Class A Common Stock. On May 20, 2026, he bought 10,000 shares at a price of $0.27 per share. After this transaction, he directly holds 1,099,073 shares of Marpai stock.
Marpai, Inc. reported a Q1 2026 net loss of $3.2M on revenue of $4.4M, with revenue down about 18% from Q1 2025 as customer turnover reduced volume. Operating loss was $2.5M and net loss per share improved to $0.13 due to a higher share count.
The balance sheet remains highly leveraged, with total liabilities of $46.2M against assets of $10.9M, resulting in stockholders’ deficit of $35.2M. Unrestricted cash was only $0.2M, while short‑term debt was about $10.3M and long‑term debt about $18.6M, including $8.3M of senior secured convertible debentures and $19.9M owed to AXA.
Operating cash flow was negative $0.5M. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital or asset sales. Marpai has extended the maturity of its debentures to April 2028, taken related‑party loans from its CEO, and is exploring strategic alternatives, including potential financings, business combinations, or a sale.
Marpai, Inc. entered into an Amendment Agreement with its Chief Executive Officer, Damien Lamendola, to extend the maturity dates of two existing promissory notes he holds. The notes have principal amounts of $410,000 and $250,000, each bearing interest at 12% per annum. Their maturities were previously April 11, 2026 and May 10, 2026, and have now been extended to September 1, 2026 for all outstanding principal and interest. All other terms and conditions of the notes remain unchanged.
SHIV SAGIV reported acquisition or exercise transactions in this Form 4 filing.
Marpai, Inc. director Shiv Sagiv received an equity grant of 100,000 shares of Class A Common Stock in the form of restricted stock units. The grant price is shown as $0.00 per share, indicating compensation rather than an open-market purchase.
According to the vesting terms, one-third of these RSUs vested on February 19, 2026, one-third vests upon execution of a Board-approved letter of intent or comparable indication of interest for a potential strategic transaction, and the final third vests upon the closing of that strategic transaction, in each case requiring continued service. After this award, Sagiv directly holds 522,000 shares of Marpai, Inc. common stock.
Marpai, Inc. files its annual report describing a technology-driven third-party administrator and pharmacy benefit manager serving self-insured employers in the U.S. The company emphasizes AI‑enabled cost containment, care management and pharmacy savings programs, operating with 107 full-time employees as of December 31, 2025.
Marpai reports substantial financial strain: an accumulated deficit of $115.4 million, negative working capital of $15.4 million, short-term debt of $11.0 million, long-term debt of $17.2 million and only $133 thousand of unrestricted cash as of December 31, 2025, alongside a $16.6 million net loss and $7.5 million negative operating cash flow for 2025.
Management and the independent auditor conclude these conditions raise substantial doubt about Marpai’s ability to continue as a going concern, and the company expects to need additional debt or equity financing or asset sales, which could significantly dilute existing stockholders. The filing also highlights a high client attrition rate of approximately 28% in 2025, customer concentration, intense competition, regulatory and cybersecurity risks, and notes that Marpai’s common stock has been delisted from Nasdaq and now trades on the OTCQX, is considered a penny stock, and may be harder for investors to trade.
Marpai, Inc. entered into a short-term financing arrangement with its Chief Executive Officer. On March 9, 2026, the company issued a $250,000 promissory note to CEO Damien Lamendola at an annual interest rate of 12.0%. The note is repayable, together with accrued interest and any other amounts due, by May 10, 2026 and can be prepaid at any time without penalty. Marpai plans to use the proceeds for general working capital needs, providing near-term liquidity funded directly by its chief executive.
Marpai, Inc. files an Amendment to Schedule 13G/A reporting beneficial ownership. The amendment states that Intelligent Fanatics Capital Management LLC, IFCM MicroCap Fund LP and Ian J. Cassel each have beneficial ownership of 1,030,085 common shares, representing 4.4% of the class as reported in the filing.
The filing shows shared voting and dispositive power of 1,030,085 shares for each reporting person and includes a statement that the Fund holds the securities directly while Mr. Cassel disclaims direct beneficial ownership except for partnership interests.
Marpai, Inc. entered into a related-party financing arrangement by issuing a promissory note for $410,000 to its Chief Executive Officer, Damien Lamendola. The note carries 12.0% annual interest and may be prepaid at any time without penalty. All principal, interest, and other amounts are due by April 11, 2026. Marpai plans to use the proceeds for general working capital needs, providing short-term liquidity funded directly by its CEO.
Marpai, Inc. reported that President Dallas Scrip resigned from his position, effective January 30, 2026. The company stated that his resignation was not due to any disagreement regarding operations, policies, or practices.
As a result, the Board appointed current Chief Executive Officer Damien Lamendola, age 70, to also serve as President effective the same date, consolidating both roles under one executive. He has been CEO since November 2023 and has served on the Board since April 2021.
The filing notes Mr. Lamendola’s prior and ongoing leadership roles at various affiliated entities and references several securities purchase agreements between Marpai, entities controlled by him, and an immediate family member, with the material terms previously disclosed and incorporated by reference. Aside from those transactions and his existing compensation, the company states there are no additional related-party transactions reportable under Item 404(a) or arrangements leading to his appointment.
Marpai, Inc. received a Schedule 13G/A filing from Intelligent Fanatics Capital Management LLC, IFCM MicroCap Fund LP, and Ian Cassel reporting a significant ownership stake. The filing states that IFCM MicroCap Fund LP beneficially owns 1,325,636 common shares, representing 5.6% of Marpai’s common stock. Intelligent Fanatics Capital Management LLC, as general partner of the fund, and Ian Cassel, as the sole managing member of IFCM, each report shared voting and shared dispositive power over these 1,325,636 shares and no sole voting or dispositive power.
The filing explains that the securities are held directly by IFCM MicroCap Fund LP and that Mr. Cassel may be deemed a beneficial owner through his interests in the fund, while he disclaims beneficial ownership beyond his economic interest. The reporting persons certify that the shares were not acquired and are not held for the purpose of changing or influencing control of Marpai.